Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up???, Annals of Oncology, vol.27, issue.suppl_5, pp.58-68, 2016. ,
DOI : 10.1093/annonc/mdw328
URL : https://academic.oup.com/annonc/article-pdf/21/suppl_5/v137/484479/mdq206.pdf
Estimation nationale de l'incidence et de la mortalité par cancer en France entre, 1980. ,
A POSTOPERATIVE PROGNOSTIC NOMOGRAM PREDICTING RECURRENCE FOR PATIENTS WITH CONVENTIONAL CLEAR CELL RENAL CELL CARCINOMA, The Journal of Urology, vol.173, issue.1, pp.48-51, 2005. ,
DOI : 10.1097/01.ju.0000148261.19532.2c
Recommandations en onco-urologie 2016-2018 du CCAFU : Cancer du rein, Progr??s en Urologie, vol.27, issue.1, pp.27-51, 2016. ,
DOI : 10.1016/S1166-7087(16)30702-3
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up??, Annals of Oncology, vol.25, issue.suppl 3, pp.49-56, 2014. ,
DOI : 10.1093/annonc/mdu259
URL : https://academic.oup.com/annonc/article-pdf/21/suppl_5/v137/484479/mdq206.pdf
Prognostic significance of morphologic parameters in renal cell carcinoma, The American Journal of Surgical Pathology, vol.6, issue.7, pp.655-63, 1982. ,
DOI : 10.1097/00000478-198210000-00007
Lymph Node Dissection in Renal Cell Carcinoma, European Urology, vol.60, issue.6, pp.1212-1232, 2011. ,
DOI : 10.1016/j.eururo.2011.09.003
Adjuvant therapy for locally advanced renal cell cancer: A systematic review with meta-analysis, BMC Cancer, vol.16, issue.Suppl 1, p.115, 2011. ,
DOI : 10.1053/j.seminoncol.2006.06.005
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy, New England Journal of Medicine, vol.375, issue.23, pp.2246-54, 2016. ,
DOI : 10.1056/NEJMoa1611406
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial, The Lancet, vol.387, issue.10032, 2016. ,
DOI : 10.1016/S0140-6736(16)00559-6
Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT) ,
Adjuvant axitinib therapy of renal cell cancer in high risk patients (ATLAS). [page consultée le 24, 2017. ,
Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer, 2017. ,
Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery (S0931). [page consultée le 20, 2017. ,
Th??rapies cibl??es n??o-adjuvantes dans le cancer du rein, Progr??s en Urologie, vol.26, issue.3, pp.191-197, 2016. ,
DOI : 10.1016/j.purol.2015.12.003
Immunotherapy for advanced renal cell cancer, Cochrane Database Syst Rev. 25 janv, issue.1, p.1425, 2005. ,
DOI : 10.1002/14651858.cd001425
Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.23, issue.1, pp.133-174, 2005. ,
DOI : 10.1200/JCO.2005.03.206
Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors, PLoS Genetics, vol.27, issue.6, p.1002312, 2011. ,
DOI : 10.1371/journal.pgen.1002312.s002
URL : https://doi.org/10.1371/journal.pgen.1002312
Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival, Journal of Clinical Oncology, vol.28, issue.13, pp.2144-50, 2010. ,
DOI : 10.1200/JCO.2009.26.7849
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.27, issue.22, pp.3584-90, 2009. ,
DOI : 10.1200/JCO.2008.20.1293
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.125-159, 2007. ,
DOI : 10.1056/NEJMoa060655
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial, The Lancet, vol.378, issue.9807, pp.1931-1940, 2011. ,
DOI : 10.1016/S0140-6736(11)61613-9
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial, Journal of Clinical Oncology, vol.28, issue.6, pp.1061-1069, 2010. ,
DOI : 10.1200/JCO.2009.23.9764
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial, The Lancet Oncology, vol.17, issue.7, pp.917-944, 2016. ,
DOI : 10.1016/S1470-2045(16)30107-3
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, The Lancet, vol.372, issue.9637, pp.449-56, 2008. ,
DOI : 10.1016/S0140-6736(08)61039-9
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.22, pp.2271-81, 2007. ,
DOI : 10.1056/NEJMoa066838
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.373, issue.19, pp.1803-1816, 2015. ,
DOI : 10.1056/NEJMoa1510665
Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib, New England Journal of Medicine, vol.370, issue.18, pp.1769-70, 2014. ,
DOI : 10.1056/NEJMc1400731
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma, Cancer, vol.28, issue.18 suppl, pp.1868-76, 2012. ,
DOI : 10.1200/JCO.2009.26.3152
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial, The Lancet, vol.358, issue.9286, pp.966-70, 2001. ,
DOI : 10.1016/S0140-6736(01)06103-7
Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer, New England Journal of Medicine, vol.345, issue.23, pp.1655-1664, 2001. ,
DOI : 10.1056/NEJMoa003013
Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma, Cancer Res. 1 août, vol.63, issue.15, pp.4481-4490, 2003. ,
Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy, BJU International, vol.95, issue.9, pp.1266-1275, 2010. ,
DOI : 10.1111/j.1349-7006.1999.tb00829.x
Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium, European Urology, vol.66, issue.4, pp.704-714, 2014. ,
DOI : 10.1016/j.eururo.2014.05.034
Expression of vascular endothelial growth factor protein in human renal cell carcinoma, BJU International, vol.49, issue.3, pp.297-302, 2004. ,
DOI : 10.1038/359843a0
Clinical Trial to Assess the Importance of Nephrectomy (CARMENA). [page consultée le 25, 2017. ,
Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME). [page consultée le 25, 2017. ,
Active surveillance for metastatic or recurrent renal cell carcinoma, Journal of Cancer Research and Clinical Oncology, vol.27, issue.8, pp.1421-1429, 2014. ,
DOI : 10.1016/j.urolonc.2007.10.017
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial, The Lancet Oncology, vol.17, issue.9, pp.1317-1341, 2016. ,
DOI : 10.1016/S1470-2045(16)30196-6
Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma, Journal of Clinical Oncology, vol.30, issue.5, pp.482-489, 2012. ,
DOI : 10.1200/JCO.2011.37.2516
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials, Cancer Treatment Reviews, vol.40, issue.2, pp.271-276, 2014. ,
DOI : 10.1016/j.ctrv.2013.09.003
Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma???Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study, European Journal of Cancer, vol.62, pp.28-35, 1990. ,
DOI : 10.1016/j.ejca.2016.04.003
Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy, Annals of Oncology, vol.22, issue.3, pp.657-63, 2011. ,
DOI : 10.1093/annonc/mdq437
Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell??Carcinoma, Clinical Genitourinary Cancer, vol.15, issue.3, pp.403-410, 2017. ,
DOI : 10.1016/j.clgc.2017.01.005
Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study, Molecular Cancer Therapeutics, vol.9, issue.6, pp.1525-1560, 2010. ,
DOI : 10.1158/1535-7163.MCT-09-1106
The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases, Acta Oncologica, vol.48, issue.6, pp.927-958, 2009. ,
DOI : 10.1080/02841860902974167
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer, Annals of Oncology, vol.24, issue.8, pp.2098-103, 2013. ,
DOI : 10.1093/annonc/mdt130
Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients, Clinical Cancer Research, vol.18, issue.14, pp.3961-71, 2012. ,
DOI : 10.1158/1078-0432.CCR-12-0002
The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer, BMC Cancer, vol.68, issue.11, p.598, 2012. ,
DOI : 10.1016/j.socscimed.2009.02.023
Review of Radiofrequency Ablation for Renal Cell Carcinoma, Clinical Cancer Research, vol.10, issue.18, pp.6328-6362, 2004. ,
DOI : 10.1158/1078-0432.CCR-050004
Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma, BJU International, vol.13, issue.6, pp.790-794, 2009. ,
DOI : 10.1097/01.RVI.0000126812.12853.77
URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2009.08459.x/pdf
Feasibility and Oncologic Control after Percutaneous Image Guided Ablation of Metastatic Renal Cell Carcinoma, The Journal of Urology, vol.192, issue.2, pp.357-63, 2014. ,
DOI : 10.1016/j.juro.2014.03.006
Determinants of Local Progression After Computed Tomography-Guided Percutaneous Radiofrequency Ablation for Unresectable Lung Tumors: 9-Year Experience in a Single Institution, CardioVascular and Interventional Radiology, vol.29, issue.4, pp.787-93, 2010. ,
DOI : 10.2214/ajr.180.1.1800151
Adenocarcinoma of the Kidney with Metastasis to the Lung: Cured by Nephrectomy and Lobectomy 1 1Read at the annual meeting of the American Association of Genito-Urinary Surgeons, Absecon, New Jersey, May 2, 1938., The Journal of Urology, vol.42, issue.3, pp.269-76, 1938. ,
DOI : 10.1016/S0022-5347(17)71516-9
Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis, The Journal of Urology, vol.197, issue.1, pp.44-53, 2017. ,
DOI : 10.1016/j.juro.2016.07.079
Local treatments for metastases of renal cell carcinoma: a systematic review, The Lancet Oncology, vol.15, issue.12, pp.549-61, 2014. ,
DOI : 10.1016/S1470-2045(14)70235-9
Long-term results of surgical resection for pulmonary metastasis from renal cell carcinoma: a 25-year singleinstitution experience. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg, févr, vol.39, issue.2, pp.167-72, 2011. ,
Resection of metastatic renal cell carcinoma., Journal of Clinical Oncology, vol.16, issue.6, pp.2261-2267, 1998. ,
DOI : 10.1200/JCO.1998.16.6.2261
Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma, Journal of Cancer Research and Clinical Oncology, vol.2015, issue.11, pp.2331-2339, 2016. ,
DOI : 10.1093/jjco/hyu171
Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma, The Journal of Urology, vol.185, issue.2, pp.439-483, 2011. ,
DOI : 10.1016/j.juro.2010.09.086
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668716/pdf
Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma, Radiotherapy and Oncology, vol.77, issue.1, pp.88-95, 2005. ,
DOI : 10.1016/j.radonc.2005.03.022
Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma, Acta Oncologica, vol.58, issue.3, pp.493-500, 2006. ,
DOI : 10.1016/j.ijrobp.2003.09.012
Stereotactic radiotherapy (SRT) for oligometastatic (OM) relapse and metastatic oligoprogression (OP) in renal cell carcinoma (RCC) patients (pts): A study of the GETUG group, J Clin Oncol, vol.34, pp.16105-16105, 2016. ,
Radiotherapie bei Hirnmetastasen eines Nierenzellkarzinoms: Sollte eine Ganzhirnbestrahlung zus??tzlich zur stereotaktischen Radiochirurgie durchgef??hrt werden? Analyse von 88 Patienten, Strahlentherapie und Onkologie, vol.37, issue.4, pp.210-217, 2010. ,
DOI : 10.1016/S0360-3016(97)00006-0
A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases, Clinical Genitourinary Cancer, vol.12, issue.1, pp.50-54, 2014. ,
DOI : 10.1016/j.clgc.2013.09.008
Radiotherapy for renal-cell carcinoma, The Lancet Oncology, vol.15, issue.4, pp.170-177, 2014. ,
DOI : 10.1016/S1470-2045(13)70569-2
How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents, Annals of Oncology, vol.20, issue.Supplement 1, pp.7-12, 2009. ,
DOI : 10.1093/annonc/mdp073
Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression, PLoS ONE, vol.16, issue.4, p.19144, 2011. ,
DOI : 10.1371/journal.pone.0019144.s001
A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma, Cancer Science, vol.40, issue.9, pp.1695-700, 2012. ,
DOI : 10.1093/jjco/hyq027
Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis, World Journal of Urology, vol.57, issue.4, pp.543-550, 2010. ,
DOI : 10.1097/01.sla.0000246847.02058.1b
Targeted therapy after complete resection of metastatic lesions in metastatic renal cell carcinoma, International Journal of Urology, vol.110, issue.2, pp.153-160, 2015. ,
DOI : 10.1111/j.1464-410X.2011.10905.x
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery. [page consultée le 08, 2017. ,
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) (PROTECT). [page consultée le 24, 2017. ,
Role of targeted therapy in combination with surgery in renal cell carcinoma, International Journal of Urology, vol.35, issue.Suppl., pp.5-12, 2016. ,
DOI : 10.14694/EdBook_AM.2015.35.e239
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma, New England Journal of Medicine, vol.372, issue.21, 2015. ,
DOI : 10.1056/NEJMoa1414428
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study, Journal of Clinical Oncology, vol.35, issue.34, 2017. ,
DOI : 10.1200/JCO.2016.72.1985